Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Vanda's HETLIOZ Meets Phase 3 Goal In Delayed Sleep-Wake Phase Disorder; Stock Up

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) reported positive topline results from a Phase 3 study of HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD).

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

More from Wednesday 30 September →